For research use only. Not for use in humans.
Molecular Weight(MW): 303.4
Vildagliptin (LAF-237) inhibits DPP−4 with IC50 of 2.3 nM.
Selleck's Vildagliptin (LAF-237) has been cited by 4 publications
Purity & Quality Control
Choose Selective DPP-4 Inhibitors
|Description||Vildagliptin (LAF-237) inhibits DPP−4 with IC50 of 2.3 nM.|
Vildagliptin is the most stable DPP-IV inhibitor, binding in the S1- and S2-catalytic sites of DPP-IV, possessing a P-1 site transition-state mimetic. 
|In vivo||Vildagliptin(orally dosed with 10 μmol/kg) is a potent, orally active inhibitor of plasma DPP-IV activity that provides increased levels of GLP-1 in an oral glucose tolerance test (OGTT) with Obese male Zucker rats. Vildagliptin orally dosed with 10 μmol/kg both significantly decreases glucose excursions and stimulates insulin secretion in Obese male Zucker rats. Maximum inhibition of plasma DPP-IV activity (95%) is observed approximately 2 hours postdose of Vildagliptin (1 μmol/kg, po) while >50% inhibition of DPP-IV is observed within 30 min postdose and persisted for >10 hours in normal Cynomolgus monkeys.  Vildagliptin(60 mg/kg) increases pancreatic beta cell mass through enhanced beta cell replication and reduced apoptosis, and the increased beta cell mass is sustained for 12 days after vildagliptin washout.  Vildagliptin administrated at doses of 10 mg/kg for 32 weeks protects nerve fiber loss in streptozotocin (STZ)-induced diabetic adult male Sprague Dawley rats. |
|In vitro||DMSO||60 mg/mL (197.75 mM)|
|Water||60 mg/mL (197.75 mM)|
|Ethanol||60 mg/mL (197.75 mM)|
|In vivo||Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
For best results, use promptly after mixing.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||interventions||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT04081857||Completed||Drug: HGP1810|Drug: HCP1704||Health Subjective||Hanmi Pharmaceutical Company Limited||June 3 2019||Phase 1|
|NCT04087525||Completed||Drug: HIP1701|Drug: HGP1809||Health Subjective||Hanmi Pharmaceutical Company Limited||October 23 2018||Phase 1|
|NCT03577184||Withdrawn||Drug: Metformin/Vildagliptin||Diabetes Mellitus Type 2||Clinision||July 2018||--|
|NCT02145611||Completed||Drug: Glibenclamide|Drug: Vildagliptin||Type 2 Diabetes Mellitus|Hypertension|Endothelial Dysfunction||Dr. José Fernando Vilela-Martin MD PhD|Novartis|Hospital de Base||July 2013||Phase 4|
|NCT01862263||Terminated||Drug: Vildagliptin|Drug: Insulin|Drug: Placebo||Type 2 Diabetes Mellitus||Novartis Pharmaceuticals|Novartis||May 2013||Phase 4|
|NCT01686932||Completed||Drug: Vildagliptin|Drug: Sitagliptin||Diabetes Mellitus Type 2||Novartis Pharmaceuticals|Novartis||November 2012||Phase 4|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.